Feeds

US pro-stem cell mission ready for fight

Bush set to veto crunch Senate vote

Boost IT visibility and business value

Scientists say the 60 cell lines the President referred to are now down to just 22. None of the pre-moratorium lines can be used in medical applications since they have been found to be contaminated by animal cells used in early culture techniques.

Explaining his moral objections, Bush continued: “Researchers are telling us the next step could be to clone human beings to create individual designer stem cells, essentially to grow another you, to be available in case you need another heart or lung or liver.”

Supporters of the Bill argue that such Brave New Worlds are actually more likely in the US given the current state of legislation. Although public money is completely steered away from research on more viable cell lines, private firms seeking to benefit commercially are free to develop technologies and tinker with embryos unchecked. Such a “head in the sand” approach is not just dumb, they say, it's dangerous.

In the UK stem cell researchers must apply to the Human Embryology and Fertilisation Authority for permission to conduct their research. Since its founding in 1991, when stem cell research was itself embryonic, the Authority has managed to sail a course that has satisfied most on both sides of the ethics versus progress debate. DeGette praised the UK's approach as “very impressive”.

The Royal Society's top stem cell expert Sir Richard Gardener cautioned against complacency in the UK though, pointing out that if science suffers in the US, effects are felt everywhere. He said: “More federally-funded research on human embryonic stem cells in the United States would increase the number of researchers who are active in this important field and thus hasten progress towards new therapies.”

When the Senate vote does happen it's likely supporters will get the majority needed to override a Bush veto. Even several “pro-life” Senators have come out against Bush on stem cell research. The House of Representatives is less likely to deliver a two thirds vote against the President however. DeGette said that if Bush does impose his moral objections she would still be hope to overturn the decision.

Langevin said: “Just as these diseases don't go away, this issue isn't going to go away”. An anti-abortionist himself, he sees no conflict between support for both embryonic stem cell scientists and his “pro-life” position. He said: “As far as I'm concerned [stem cell technology] offers hope to millions. What could be more pro-life than that?”®

Boost IT visibility and business value

More from The Register

next story
Just TWO climate committee MPs contradict IPCC: The two with SCIENCE degrees
'Greenhouse effect is real, but as for the rest of it ...'
BEST BATTERY EVER: All lithium, all the time, plus a dash of carbon nano-stuff
We have found the Holy Grail (of batteries) - boffins
Asteroid's DINO KILLING SPREE just bad luck – boffins
Sauricide WASN'T inevitable, reckon scientists
Flamewars in SPAAACE: cooler fires hint at energy efficiency
Experiment aboard ISS shows we should all chill out for cleaner engines
The Sun took a day off last week and made NO sunspots
Someone needs to get that lazy star cooking again before things get cold around here
Boffins discuss AI space program at hush-hush IARPA confab
IBM, MIT, plenty of others invited to fill Uncle Sam's spy toolchest, but where's Google?
Famous 'Dish' radio telescope to be emptied in budget crisis: CSIRO
Radio astronomy suffering to protect Square Kilometre Array
prev story

Whitepapers

Implementing global e-invoicing with guaranteed legal certainty
Explaining the role local tax compliance plays in successful supply chain management and e-business and how leading global brands are addressing this.
The Essential Guide to IT Transformation
ServiceNow discusses three IT transformations that can help CIO's automate IT services to transform IT and the enterprise.
Consolidation: The Foundation for IT Business Transformation
In this whitepaper learn how effective consolidation of IT and business resources can enable multiple, meaningful business benefits.
How modern custom applications can spur business growth
Learn how to create, deploy and manage custom applications without consuming or expanding the need for scarce, expensive IT resources.
Build a business case: developing custom apps
Learn how to maximize the value of custom applications by accelerating and simplifying their development.